BOT - Anything but charting, page-884

Let's remember that on the 16th of May the ASX forced BOT to make a retraction regarding its antimicrobial program and the claim - which then turned out to be true -that "bacteria do not form resistance to BTX1801".
It makes sense then to delay disclosure to the ASX of any 'in-vivo/in-vitro' (?) acquired data till there's further confirmation, it's nonetheless a smart move from BOT to lodge patent applications on 'preliminary' (?) data.
In any case, re-reading the announcement from the 15th of October it becomes apparent that their synthetic cannabidiol analog program was well advanced then:
"Botanix has created a library of novel cannabidiol analogs with varying characteristics that show
properties of the natural cannabidiol molecule can be enhanced without sacrificing activity."

In a market with a track record of misinterpreting positive data as 'negative' (like with the late Phase II), BOT 's choice of playing its card close to its chest can be appreciated.